Pleomorphic adenoma is the most common benign salivary gland neoplasm principally affecting the parotid gland of the salivary gland and the palate of the minor salivary gland. The term pleomorphic is assigned due to its varied histopathological presentation. We hereby describe a rare case of pleomorphic adenoma in a male patient in his 7th decade of life complaining of swelling in the hard palate for the past 3 years. This case report emphasizes the unique representation of squamous and lipomatous differentiation which was erroneously diagnosed as OSCC or mucoepidermoid carcinoma. We have also included a literature search of such cases that exhibited lipomatous and squamous differentiation in PA listed from the last 10 years.
{"title":"Variable metaplastic entities in pleomorphic adenoma a review of a rare case report with a note on its significance","authors":"N. Mahapatra, L. Bhuyan, Dash Chandra, P. Mishra","doi":"10.2298/aoo230329005m","DOIUrl":"https://doi.org/10.2298/aoo230329005m","url":null,"abstract":"Pleomorphic adenoma is the most common benign salivary gland neoplasm principally affecting the parotid gland of the salivary gland and the palate of the minor salivary gland. The term pleomorphic is assigned due to its varied histopathological presentation. We hereby describe a rare case of pleomorphic adenoma in a male patient in his 7th decade of life complaining of swelling in the hard palate for the past 3 years. This case report emphasizes the unique representation of squamous and lipomatous differentiation which was erroneously diagnosed as OSCC or mucoepidermoid carcinoma. We have also included a literature search of such cases that exhibited lipomatous and squamous differentiation in PA listed from the last 10 years.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135666778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anastasiya Snezhkina, Maria Fedorova, Asiya Ayupova, Elena Pudova, Anastasiya Kobelyatskaya, Dmitry Kalinin, Alexander Golovyuk, George Krasnov, Vladislav Pavlov, Anna Kudryavtseva
Background: Vagal paraganglioma (VPGL) is a very rare neuroendocrine tumor arising from the paraganglion associated with the vagus nerve. VPGL is mainly characterized by an asymptomatic course and slow growth. However, up to 19% of tumors can metastasize. Due to the rarity of this tumor, information about VPGL is limited to single cases and small sample sets; the data on molecular genetic features is extremely scarce. Methods: For the first time we have analyzed the enrichment of biological pathways associated with mutations in the SDHx genes in VPGLs. Bioinformatics analysis was performed based on the results of high-throughput transcriptome sequencing on an Illumina platform for 33 tumor tissues obtained from patients with vagal paragangliomas. Results: Eight pathways of the Kyoto Encyclopedia of Genes and Genomes (KEGG) database with gene overrepresentation (top-40 mode) have been identified. Significant changes were shown for the cancer-associated PI3K-Akt signaling pathway and interconnected pathways of focal adhesion and interaction of receptors with the extracellular matrix enriched by overexpressed genes. Conclusion: Our result indicates the association of SDHx mutations with changes in the PI3K-Akt signaling pathway in vagal paraganglioma. The potential mechanism of deregulation in this pathway could be linked with a state of pseudohypoxia induced by the dysfunction of succinate dehydrogenase due to mutations in the SDHx genes.
{"title":"SDHx mutations are associated with the PI3K-Akt signaling pathway in vagal paragangliomas","authors":"Anastasiya Snezhkina, Maria Fedorova, Asiya Ayupova, Elena Pudova, Anastasiya Kobelyatskaya, Dmitry Kalinin, Alexander Golovyuk, George Krasnov, Vladislav Pavlov, Anna Kudryavtseva","doi":"10.2298/aoo230608004s","DOIUrl":"https://doi.org/10.2298/aoo230608004s","url":null,"abstract":"Background: Vagal paraganglioma (VPGL) is a very rare neuroendocrine tumor arising from the paraganglion associated with the vagus nerve. VPGL is mainly characterized by an asymptomatic course and slow growth. However, up to 19% of tumors can metastasize. Due to the rarity of this tumor, information about VPGL is limited to single cases and small sample sets; the data on molecular genetic features is extremely scarce. Methods: For the first time we have analyzed the enrichment of biological pathways associated with mutations in the SDHx genes in VPGLs. Bioinformatics analysis was performed based on the results of high-throughput transcriptome sequencing on an Illumina platform for 33 tumor tissues obtained from patients with vagal paragangliomas. Results: Eight pathways of the Kyoto Encyclopedia of Genes and Genomes (KEGG) database with gene overrepresentation (top-40 mode) have been identified. Significant changes were shown for the cancer-associated PI3K-Akt signaling pathway and interconnected pathways of focal adhesion and interaction of receptors with the extracellular matrix enriched by overexpressed genes. Conclusion: Our result indicates the association of SDHx mutations with changes in the PI3K-Akt signaling pathway in vagal paraganglioma. The potential mechanism of deregulation in this pathway could be linked with a state of pseudohypoxia induced by the dysfunction of succinate dehydrogenase due to mutations in the SDHx genes.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134884273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ljuban Blanusa, Aleksandra Lovrenski, Marija Baros-Brkljaca
Background: Metastatic tumors are tumors whose primary origin is not the organ in which they are located, but have reached the target tissue by metastasis from the primary site of the tumor. The presence of metastases of the primary tumor in other organs is responsible for the highest number of cancer mortality, and in addition, their presence significantly changes the treatment of an oncologic patient in relation to a patient whom the primary tumor is not disseminated. The goal of this study was to determine the importance of immunohistochemistry in the diagnosis of metastatic lung tumors. Methods: A retrospective study included 84 patients with a pathohistologically proven metastatic lung disease at the Institute of Pulmonary Diseases of Vojvodina from April 1 2013 to March 31 2018. Material for pathohistological and immunohistochemical analysis was studied in the Institute for Histopathology and Molecular Diagnostics of the Institute. Results: Out of a total of 84 patients, in 42 (50%) patients, the origin of pulmonary metastases was colorectal cancer, 15 (17%) renal cell carcinoma, 11 (13%) breast cancer, 4 (4%) malignant melanoma, 3 (4%) leiomyosarcoma of the uterus, and in the other 9 (11%) individual tumor cases. Antibodies used in the immunohistochemical assay are CK20 and CDX2 (colorectal cancer), CD10, RCC, Vimentin (renal cell carcinoma), PR, ER, Mamaglobin (breast cancer), HMB45, S100, Vimentin, MelanA (melanoma) SMA, Myosin, Desmin (uterine leiomyosarcoma). Conclusion: For the purpose of faster and more precise diagnostic and timely treatment of patients with disseminated malignant disease, it is necessary to supplement the standard pathohistological analysis with immunohistochemistry analysis, which is an important method in determining the primary origin of metastatic tumors.
{"title":"The role of immunohistochemical analysis in the diagnosis of lung metastases","authors":"Ljuban Blanusa, Aleksandra Lovrenski, Marija Baros-Brkljaca","doi":"10.2298/aoo220825001b","DOIUrl":"https://doi.org/10.2298/aoo220825001b","url":null,"abstract":"Background: Metastatic tumors are tumors whose primary origin is not the organ in which they are located, but have reached the target tissue by metastasis from the primary site of the tumor. The presence of metastases of the primary tumor in other organs is responsible for the highest number of cancer mortality, and in addition, their presence significantly changes the treatment of an oncologic patient in relation to a patient whom the primary tumor is not disseminated. The goal of this study was to determine the importance of immunohistochemistry in the diagnosis of metastatic lung tumors. Methods: A retrospective study included 84 patients with a pathohistologically proven metastatic lung disease at the Institute of Pulmonary Diseases of Vojvodina from April 1 2013 to March 31 2018. Material for pathohistological and immunohistochemical analysis was studied in the Institute for Histopathology and Molecular Diagnostics of the Institute. Results: Out of a total of 84 patients, in 42 (50%) patients, the origin of pulmonary metastases was colorectal cancer, 15 (17%) renal cell carcinoma, 11 (13%) breast cancer, 4 (4%) malignant melanoma, 3 (4%) leiomyosarcoma of the uterus, and in the other 9 (11%) individual tumor cases. Antibodies used in the immunohistochemical assay are CK20 and CDX2 (colorectal cancer), CD10, RCC, Vimentin (renal cell carcinoma), PR, ER, Mamaglobin (breast cancer), HMB45, S100, Vimentin, MelanA (melanoma) SMA, Myosin, Desmin (uterine leiomyosarcoma). Conclusion: For the purpose of faster and more precise diagnostic and timely treatment of patients with disseminated malignant disease, it is necessary to supplement the standard pathohistological analysis with immunohistochemistry analysis, which is an important method in determining the primary origin of metastatic tumors.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135210926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Many studies have shown that geriatric patients with altered nutritional status are at higher risk of developing complications during medical treatment. Our study aimed to examine the role of preoperative nutritional status in developing postoperative complications and the length of hospital stay in geriatric patients who suffer from cancer and undergo major abdominal surgery. Methods: Prospective research was conducted at the Oncology Institute of Vojvodina from January 2020 until April 2021. This study included 82 patients over 65 years old, who were admitted to have radical surgery for gastrointestinal cancer performed. There were 6 patients excluded from the study. Nutritional status analysis was performed using BMI (Body mass index), preoperative serum albumin level, MNA-SF (Mini nutritional assessment-short form), and GNRI (Geriatric nutritional risk index). The classification of surgical complications was done using the Clavien-Dindo classification scale. Results: Of the total number of patients, 57 of them (75%) developed at least one surgical complication. Nonsurgical complications have been recognized in 28 patients (36.84%). Overweight patients, according to BMI, had a greater chance of developing grade I (p < 0.01) and grade II (p < 0.05) surgical complications of the Clavien-Dindo classification. Patients with normal serum albumin levels had a significantly lower chance of developing surgical complications of any grade (p = 0.00). BMI and MNA-SF were the most important predictors of delirium. Patients without GNRI risk (GNRI: >98) had a significantly lower chance of developing nonsurgical complications regarding comorbidity exacerbation (p = 0.03), and delirium (p = 0.00). Conclusion: None of the nutritional assessment tools used in our study were better or more efficient than the others in our sample of patients. Precise nutritional status assessment is complex and we cannot use only one scoring system or scale to get accurate results.
{"title":"The role of the nutritional status of geriatric patients with gastrointestinal cancer in developing postoperative complications","authors":"Sanja Starcevic, Dragana Radovanovic, Svetlana Skoric-Jokic, Nora Mihalek, Danica Golijanin","doi":"10.2298/aoo221120002s","DOIUrl":"https://doi.org/10.2298/aoo221120002s","url":null,"abstract":"Background: Many studies have shown that geriatric patients with altered nutritional status are at higher risk of developing complications during medical treatment. Our study aimed to examine the role of preoperative nutritional status in developing postoperative complications and the length of hospital stay in geriatric patients who suffer from cancer and undergo major abdominal surgery. Methods: Prospective research was conducted at the Oncology Institute of Vojvodina from January 2020 until April 2021. This study included 82 patients over 65 years old, who were admitted to have radical surgery for gastrointestinal cancer performed. There were 6 patients excluded from the study. Nutritional status analysis was performed using BMI (Body mass index), preoperative serum albumin level, MNA-SF (Mini nutritional assessment-short form), and GNRI (Geriatric nutritional risk index). The classification of surgical complications was done using the Clavien-Dindo classification scale. Results: Of the total number of patients, 57 of them (75%) developed at least one surgical complication. Nonsurgical complications have been recognized in 28 patients (36.84%). Overweight patients, according to BMI, had a greater chance of developing grade I (p < 0.01) and grade II (p < 0.05) surgical complications of the Clavien-Dindo classification. Patients with normal serum albumin levels had a significantly lower chance of developing surgical complications of any grade (p = 0.00). BMI and MNA-SF were the most important predictors of delirium. Patients without GNRI risk (GNRI: >98) had a significantly lower chance of developing nonsurgical complications regarding comorbidity exacerbation (p = 0.03), and delirium (p = 0.00). Conclusion: None of the nutritional assessment tools used in our study were better or more efficient than the others in our sample of patients. Precise nutritional status assessment is complex and we cannot use only one scoring system or scale to get accurate results.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135210937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A potential complication that affects a patient's quality of life is breast Cancer-related lymphedema (BCRL). Due to lymphatic system failure brought on by breast Cancer treatment, it is secondary lymphedema. This literature review examines 50 articles that are connected to BCRL. Research conducted in the English language between 2017 and 2022 is included. The definition, occurrence, severity, symptoms, risk factors, aspects of quality of life, and total decongestive therapy are all incorporated in this review of BCRL. The severity of the BCRL is assessed using International Staging Lymphology, 2020 from mild to severe. The documented incidence rates of BCRL in the literature range greatly, between less than 5% and more than 50%. The most significant risk factors of BCRL are related to lymph node surgery, in particular, axillary lymph node excision, and radiation therapy. If BCRL is not properly diagnosed and managed, it could have debilitating, long-lasting and late crippling side-effects of breast Cancer treatment. It frequently has a devastating impact on the quality of life in many domains. To better understand the behaviors and management of lymphedema risk reduction, patients with breast Cancer need extra information. To evaluate the effectiveness of complete decongestive therapy as a risk reduction behavior rather than for management and treatment, more study needs be done with a larger sample and longer supervision.
{"title":"Literature review on breast cancer-related lymphedema and related factors","authors":"Shaimaa Shamoun, Muayyad Ahmad","doi":"10.2298/aoo230313003s","DOIUrl":"https://doi.org/10.2298/aoo230313003s","url":null,"abstract":"A potential complication that affects a patient's quality of life is breast Cancer-related lymphedema (BCRL). Due to lymphatic system failure brought on by breast Cancer treatment, it is secondary lymphedema. This literature review examines 50 articles that are connected to BCRL. Research conducted in the English language between 2017 and 2022 is included. The definition, occurrence, severity, symptoms, risk factors, aspects of quality of life, and total decongestive therapy are all incorporated in this review of BCRL. The severity of the BCRL is assessed using International Staging Lymphology, 2020 from mild to severe. The documented incidence rates of BCRL in the literature range greatly, between less than 5% and more than 50%. The most significant risk factors of BCRL are related to lymph node surgery, in particular, axillary lymph node excision, and radiation therapy. If BCRL is not properly diagnosed and managed, it could have debilitating, long-lasting and late crippling side-effects of breast Cancer treatment. It frequently has a devastating impact on the quality of life in many domains. To better understand the behaviors and management of lymphedema risk reduction, patients with breast Cancer need extra information. To evaluate the effectiveness of complete decongestive therapy as a risk reduction behavior rather than for management and treatment, more study needs be done with a larger sample and longer supervision.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134882801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Pretreatment differentiation between glioblastoma and metastasis is a frequently encountered dilemma in neurosurgical practice. Distinction is required for precise planning of resection or radiotherapy, and also for defining further diagnostic procedures. Morphology and spectroscopy imaging features are not specific and frequently overlap. This limitation of magnetic resonance imaging and magnetic resonance spectroscopy was the reason to initiate this study. The aim of the present study was to determine whether the dataset of diffusion tensor imaging metrics contains information which may be used for the distinction between primary and secondary intra-axial neoplasms. Methods: Two diffusion tensor imaging parameters were measured in 81 patients with an expansive, ring-enhancing, intra-axial lesion on standard magnetic resonance imaging (1.5 T system). All tumors were histologically verified glioblastoma or secondary deposit. For qualitative analysis, two regions of interest were defined: intratumoral and immediate peritumoral region (locations 1 and 2, respectively). Fractional anisotropy and mean difusivity values of both groups were compared. Additional test was performed to determine if there was a significant difference in mean values between two locations. Results: A statistically significant difference was found in fractional anisotropy values among two locations, with decreasing values in the direction of neoplastic infiltration, although such difference was not observed in fractional anisotropy values in the group with secondary tumors. Mean difusivity values did not appear helpful in differentiation between these two entities. In both groups there was no significant difference in mean difusivity values, neither in intratumoral nor in peritumoral location. Conclusion: The results of our study justify associating the diffusion tensor imaging technique to conventional morphologic magnetic resonance imaging as an additional diagnostic tool for the distinction between primary and secondary intra-axial lesions. Quantitative analysis of diffusion tensor imaging metric, in particular measurement of fractional anisotropy in peritumoral edema facilitates accurate diagnosis.
{"title":"Diffusion tensor imaging derived metrics in high grade glioma and brain metastasis differentiation","authors":"Alma Brakus, J. Ostojić, M. Lucic","doi":"10.2298/aoo210828007b","DOIUrl":"https://doi.org/10.2298/aoo210828007b","url":null,"abstract":"Background: Pretreatment differentiation between glioblastoma and metastasis is a frequently encountered dilemma in neurosurgical practice. Distinction is required for precise planning of resection or radiotherapy, and also for defining further diagnostic procedures. Morphology and spectroscopy imaging features are not specific and frequently overlap. This limitation of magnetic resonance imaging and magnetic resonance spectroscopy was the reason to initiate this study. The aim of the present study was to determine whether the dataset of diffusion tensor imaging metrics contains information which may be used for the distinction between primary and secondary intra-axial neoplasms. Methods: Two diffusion tensor imaging parameters were measured in 81 patients with an expansive, ring-enhancing, intra-axial lesion on standard magnetic resonance imaging (1.5 T system). All tumors were histologically verified glioblastoma or secondary deposit. For qualitative analysis, two regions of interest were defined: intratumoral and immediate peritumoral region (locations 1 and 2, respectively). Fractional anisotropy and mean difusivity values of both groups were compared. Additional test was performed to determine if there was a significant difference in mean values between two locations. Results: A statistically significant difference was found in fractional anisotropy values among two locations, with decreasing values in the direction of neoplastic infiltration, although such difference was not observed in fractional anisotropy values in the group with secondary tumors. Mean difusivity values did not appear helpful in differentiation between these two entities. In both groups there was no significant difference in mean difusivity values, neither in intratumoral nor in peritumoral location. Conclusion: The results of our study justify associating the diffusion tensor imaging technique to conventional morphologic magnetic resonance imaging as an additional diagnostic tool for the distinction between primary and secondary intra-axial lesions. Quantitative analysis of diffusion tensor imaging metric, in particular measurement of fractional anisotropy in peritumoral edema facilitates accurate diagnosis.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68403542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Colon cancer is a leading cause of cancer-related deaths worldwide. About 10% of all colon cancer patients are found to have a mutation in BRAF proto-oncogene that arise as a result of a substitution of amino acid valine with glutamate at position 600 (V600E). This specific mutation is also found in melanomas, but at even higher percent - in up to 60% of patients. A particular category of drugs called BRAF inhibitors, have been developed in order to increase survival. But, while in patients with melanoma this class of drugs work well especially when combined with mitogen-activated protein kinase inhibitors, they have low efficacy in patients with metastatic colorectal cancer suggesting different mechanism of action and development of drug resistance. This review summarise recent findings aimed to highlight events in BRAF mutations in metastatic colorectal cancer.
{"title":"BRAF mutation in colorectal cancer: An update","authors":"A. Colombo, C. Porretto","doi":"10.2298/aoo220130004c","DOIUrl":"https://doi.org/10.2298/aoo220130004c","url":null,"abstract":"Colon cancer is a leading cause of cancer-related deaths worldwide. About 10% of all colon cancer patients are found to have a mutation in BRAF proto-oncogene that arise as a result of a substitution of amino acid valine with glutamate at position 600 (V600E). This specific mutation is also found in melanomas, but at even higher percent - in up to 60% of patients. A particular category of drugs called BRAF inhibitors, have been developed in order to increase survival. But, while in patients with melanoma this class of drugs work well especially when combined with mitogen-activated protein kinase inhibitors, they have low efficacy in patients with metastatic colorectal cancer suggesting different mechanism of action and development of drug resistance. This review summarise recent findings aimed to highlight events in BRAF mutations in metastatic colorectal cancer.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68403110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Pavlushenko, R. Liubota, R. Vereshchako, N. Anikusko, I. Liubota
Cancer presents significant hurdle in the goal to increase the life expectancy of the world population. In 2020 breast cancer has become the leading cause of global cancer in the female population, ahead of lung cancer. Over the past half century, approach to the treatment of breast cancer has changed dramatically that led to improvement of survival rates and quality of life of patients. In particular, the changes affected the surgical treatment of breast cancer. The modern tactics of treating breast cancer patients has become more complex and requires a multidisciplinary approach led by an oncological surgeon. It requires the availability of specialized material and equipment in medical institutions and practical skills of surgeons that provide medical care to breast cancer patients. However, breast cancer patients may not receive the entire range of modern treatment options, due to limited capabilities of medical institution and/or surgeon that leads to deterioration in duration and quality of life of patients. The quality of medical care for breast cancer patients is directly proportional to the number of cases performed annually at a medical institution (hospital volume) or by a surgeon (surgeon volume). The results of this study can serve as a basis for further investigations of the relationship between the surgeon and hospital volume and other factors affecting the quality and diversity of medical care for breast cancer patients.
{"title":"Effects of surgeon volume and hospital volume on clinical outcomes of breast cancer patients","authors":"M. Pavlushenko, R. Liubota, R. Vereshchako, N. Anikusko, I. Liubota","doi":"10.2298/aoo210720006p","DOIUrl":"https://doi.org/10.2298/aoo210720006p","url":null,"abstract":"Cancer presents significant hurdle in the goal to increase the life expectancy of the world population. In 2020 breast cancer has become the leading cause of global cancer in the female population, ahead of lung cancer. Over the past half century, approach to the treatment of breast cancer has changed dramatically that led to improvement of survival rates and quality of life of patients. In particular, the changes affected the surgical treatment of breast cancer. The modern tactics of treating breast cancer patients has become more complex and requires a multidisciplinary approach led by an oncological surgeon. It requires the availability of specialized material and equipment in medical institutions and practical skills of surgeons that provide medical care to breast cancer patients. However, breast cancer patients may not receive the entire range of modern treatment options, due to limited capabilities of medical institution and/or surgeon that leads to deterioration in duration and quality of life of patients. The quality of medical care for breast cancer patients is directly proportional to the number of cases performed annually at a medical institution (hospital volume) or by a surgeon (surgeon volume). The results of this study can serve as a basis for further investigations of the relationship between the surgeon and hospital volume and other factors affecting the quality and diversity of medical care for breast cancer patients.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68403487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tatjana Petrovic-Majstorovic, M. Jukovic, Gordana Vujasinović, D. Dragišić, Nemanja Petrovic
Group of symptoms due to vena cava superior obstruction is named superior vena cava syndrome. A 65-year-old female, long-standing smoker was presented with a two-week history of dry cough and facial swelling. The patient noticed a palpable mass on the right side of the neck. Computer tomography scan with contrast showed extensive, irregular, non-homogenous consolidation in the right upper lobe, involving the right hilus, surrounding the aortic arch, supra aortic branches and pleural effusion at the right side of the body. Also, ultrasound examination of supra clavicular space showed enlarged pathologic hypoehogenic lymph node without an echogenic hilum. Ultrasound guided fine needle biopsy of lymph node was performed, and cytopathology findings showed metastatic lesion from primary microcellular lung cancer, IIIC stadium, cT4N3M0. Venous angioplasty was performed showing stenosis in the superior vena cava (the first type of Stanford classification). After balloon dilatation, the stent was placed at the site of stenosis. The patient received chemio- and radiotherapy and survival time was seven months. Superior vena cava syndrome is an urgent clinical condition, and lung cancer is the leading cause of this syndrome. Computer tomography imaging findings and endovascular stent placement are important for detection and management of the superior vena cava thrombosis.
{"title":"Tumor mass in the lung with superior vena cava syndrome","authors":"Tatjana Petrovic-Majstorovic, M. Jukovic, Gordana Vujasinović, D. Dragišić, Nemanja Petrovic","doi":"10.2298/aoo200521002p","DOIUrl":"https://doi.org/10.2298/aoo200521002p","url":null,"abstract":"Group of symptoms due to vena cava superior obstruction is named superior vena cava syndrome. A 65-year-old female, long-standing smoker was presented with a two-week history of dry cough and facial swelling. The patient noticed a palpable mass on the right side of the neck. Computer tomography scan with contrast showed extensive, irregular, non-homogenous consolidation in the right upper lobe, involving the right hilus, surrounding the aortic arch, supra aortic branches and pleural effusion at the right side of the body. Also, ultrasound examination of supra clavicular space showed enlarged pathologic hypoehogenic lymph node without an echogenic hilum. Ultrasound guided fine needle biopsy of lymph node was performed, and cytopathology findings showed metastatic lesion from primary microcellular lung cancer, IIIC stadium, cT4N3M0. Venous angioplasty was performed showing stenosis in the superior vena cava (the first type of Stanford classification). After balloon dilatation, the stent was placed at the site of stenosis. The patient received chemio- and radiotherapy and survival time was seven months. Superior vena cava syndrome is an urgent clinical condition, and lung cancer is the leading cause of this syndrome. Computer tomography imaging findings and endovascular stent placement are important for detection and management of the superior vena cava thrombosis.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68403186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Diffuse large B cell lymphoma is a heterogeneous tumor group consisting of large and transformed B cells that makeup 30-40% of all non-Hodgkin lymphoma. Numerous studies point out that initial parameters and post-treatment responses can be used as prognostic factors. We aimed to examine the relationship between diagnosis, clinical and laboratory parameters, treatment response and survival using neutrophil-lymphocyte and monocyte-lymphocyte ratios. Methods: A total of 80 patients, followed in our hematology clinic between January 2009-2019, were included in the study and were analyzed retrospectively. Results: The median value of neutrophil- lymphocyte ratio was 3.5 (0.3-50.2) and of monocyte/lymphocyte ratio was 0.3 (0.1-4.8). In the group with neutrophil-lymphocyte ratio ? 3.5 response rates was significantly lower and exitus rate and the bulky mass presence were significantly higher compared to the group with > 3.5 values (p < 0.05). In the group with monocyte-lymphocyte ratio ? 0.30, the exitus rate was significantly higher compared to group with < 0.30 values (p < 0.05). Conclusion: A statistically significant bulky mass presence was demonstrated in the population above the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio cut off. Although not considered to be sufficient alone, these parameters could be used as prognostic factors in combination with current scoring systems.
{"title":"Pre-treatment neutrophil-lymphocyte and monocyte-lymphocyte ratios give clues about response, survival, and recurrence in diffuse large B-cell lymphoma","authors":"B. Demir, I. Serin, DoguMehmet Hilmi","doi":"10.2298/aoo201122003d","DOIUrl":"https://doi.org/10.2298/aoo201122003d","url":null,"abstract":"Background: Diffuse large B cell lymphoma is a heterogeneous tumor group consisting of large and transformed B cells that makeup 30-40% of all non-Hodgkin lymphoma. Numerous studies point out that initial parameters and post-treatment responses can be used as prognostic factors. We aimed to examine the relationship between diagnosis, clinical and laboratory parameters, treatment response and survival using neutrophil-lymphocyte and monocyte-lymphocyte ratios. Methods: A total of 80 patients, followed in our hematology clinic between January 2009-2019, were included in the study and were analyzed retrospectively. Results: The median value of neutrophil- lymphocyte ratio was 3.5 (0.3-50.2) and of monocyte/lymphocyte ratio was 0.3 (0.1-4.8). In the group with neutrophil-lymphocyte ratio ? 3.5 response rates was significantly lower and exitus rate and the bulky mass presence were significantly higher compared to the group with > 3.5 values (p < 0.05). In the group with monocyte-lymphocyte ratio ? 0.30, the exitus rate was significantly higher compared to group with < 0.30 values (p < 0.05). Conclusion: A statistically significant bulky mass presence was demonstrated in the population above the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio cut off. Although not considered to be sufficient alone, these parameters could be used as prognostic factors in combination with current scoring systems.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68403308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：